Muscle damage elicits a sterile immune response that facilitates complete regeneration. Here, we used mass spectrometrybased lipidomics to map the mediator lipidome during the transition from inflammation to resolution and regeneration in skeletal muscle injury. We observed temporal regulation of glycerophospholipids and production of pro-inflammatory lipid mediators (for example, leukotrienes and prostaglandins) and specialized pro-resolving lipid mediators (for example, resolvins and lipoxins) that were modulated by ibuprofen. These time-dependent profiles were recapitulated in sorted neutrophils and Ly6C hi and Ly6C lo muscle-infiltrating macrophages, with a distinct pro-resolving signature observed in Ly6C lo macrophages. RNA sequencing of macrophages stimulated with resolvin D2 showed similarities to transcriptional changes found during the temporal transition from Ly6C hi macrophage to Ly6C lo macrophage. In vivo, resolvin D2 increased Ly6C lo macrophages and functional improvement of the regenerating muscle. These results reveal dynamic lipid mediator signatures of innate immune cells and provide a proof of concept for their exploitable effector roles in muscle regeneration. 
C ells of the innate immune system undergo dynamic changes in population size, differentiation state and function in response to diverse stimuli to maintain organismal integrity 1 . However, dysregulated innate immune responses can contribute to disease 2, 3 . Due to their roles in the initiation, maintenance and resolution during wound-healing and regeneration in different organ systems, myeloid cells, including macrophages, are therapeutic targets 4, 5 . Our knowledge is fragmented as to how macrophages change their phenotype, employ sensory and regulatory mechanisms and use effector functions to serve such roles. This is important because proper signaling between macrophages and other cells can ensure precisely timed repair while avoiding asynchrony, leading to regeneration delay, fibrosis and/or chronic inflammation 2, 3 . Injury in skeletal muscle is characterized by production of proinflammatory mediators including cytokines, followed by myeloid cell recruitment. Termination of pro-inflammatory mediator production and subsequent apoptotic cell clearance defines the resolution phase, which couples to tissue repair and regeneration 6 . Macrophages are involved in each of these phases, including clearance of necrotic debris, apoptotic cells and tissue repair 7 . Pharmacologic or genetic depletion of macrophages impairs muscle regeneration. This process is characterized by an in situ transition of infiltrating monocytes to inflammatory (Ly6C hi ) and to repair (Ly6C lo ) macrophages 8 , indispensable for proper regeneration 9, 10 . Cues from the microenvironment drive temporal gene-expression changes characteristic of the switch from an inflammatory to a repair phenotype 8 . The signals regulating these phenotypes remain of interest.
Lipid mediators play key roles in the initiation and resolution of inflammation 11 . They are generated by immune cells (for example, neutrophils and macrophages) and have direct receptor-mediated actions on them. Remodeling of membrane phospholipids occurs on cellular activation, as esterified polyunsaturated fatty acids (PUFA) are liberated for conversion to lipid mediators 12 . They are enzymatically generated from PUFA, including arachidonic acid, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), through the action of cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P 450 monooxygenases. These include pro-inflammatory eicosanoids such as leukotrienes (for example, LTB 4 , LTC 4 ), which regulate microvascular permeability and leukocyte recruitment, and prostaglandins (for example, PGE 2 ) that regulate blood vessel tone, pro-inflammatory signaling and thrombosis 13 . In contrast, specialized pro-resolving lipid mediators (SPMs), including resolvins (for example, RvD1, RvD2, RvE1), are produced during resolution and actively signal the termination of pro-inflammatory mediator production, promote macrophage efferocytosis and enhance host defense 11, 14, 15 . SPMs are generated in humans in inflammatory exudates at bioactive levels and, when added back to human blisters, reduce neutrophil numbers [16] [17] [18] . SPMs can improve pathological manifestations of chronic inflammation 19, 20 . Moreover, some SPMs actively promote tissue repair in the skin and the eye, and accelerate tissue regeneration in planaria [21] [22] [23] . Here we mapped the global structural lipid and lipid mediator profiles during muscle injury and regeneration, investigated specific lipid mediator signatures of innate immune cell subsets and integrated this information
Dynamic changes to lipid mediators support transitions among macrophage subtypes during muscle regeneration
Lipid mediator class switching occurs during muscle regeneration. PUFA-derived lipid mediators have important roles in the initiation and resolution of inflammation. To investigate the production of lipid mediators during muscle injury, we conducted targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) at days 1, 2, 4 and 8 following injury. We assessed the main families of pro-inflammatory lipid mediators (for example, leukotrienes, prostaglandins) and SPMs (for example, resolvins, lipoxins, protectins, maresins), as well as their biosynthetic pathway markers. The abundance of each mediator was quantitated using extraction recovery of deuterated internal standards and calibration curves of external standards for each lipid mediator, identified on the basis of retention time and diagnostic fragmentation ion assignments (see Methods). Lipid mediators and their biosynthetic pathway markers were identified across the arachidonic acid, EPA and DHA bioactive metabolomes (Fig. 2a-c) .
We subdivided each of the lipid classes and compared the contribution of each to the entire lipid mediator pool at days 0, 1, 2, 4 and 8 post-injury. We observed a shift from greater levels of pro-inflammatory mediators (prostaglandins and leukotrienes) at days 1 and 2 to SPMs (lipoxins and resolvins) at days 2-8 ( Fig. 2c) . The proportions of each class to the whole pool of lipid mediators at day 8 were similar to day 0 (Fig. 2c) . Next, we examined the relative changes of each individual lipid mediator over the regeneration time course. Levels of nearly all lipid mediators increased at day 1 and 2 compared with baseline; many of the pro-inflammatory lipid mediators (LTB 4 , PGE 2 , PGF 2α ) then decreased by day 4, while most SPMs (RvE2, RvE1, RvD5, RvD2, RvE3, LXB 4 ) and their pathway markers remained elevated at day 4 compared with their baseline levels (Fig. 2d,e and Supplementary Table 1b) . Comparison of the ratio of LTB 4 to the total amount of SPMs at days 2 and 4 also indicated a switch from pro-inflammatory to pro-resolving mediators (Fig. 2f) . Collectively, these results indicate the dynamic class switching of lipid mediators during injury and regeneration in skeletal muscle.
Lipid mediator class switching occurs during exercise injury. Next, we used targeted LC-MS/MS to assess the lipidomic changes that occur in eccentric exercise-induced injury (model described in Methods) 25, 26 , which is more pathophysiologically relevant than the CTX-induced injury. We used interaction network pathway analyses to visualize changes in lipid mediator metabolomes from arachidonic acid, EPA and DHA at day 1 post-injury compared to day 0 in both the CTX-and eccentric exercise-induced injury (Fig. 3a,b ). This analysis integrates pathway relationships with lipid mediator abundance and fold change versus baseline (day 0). The mediators identified and their direction of change were largely consistent between the CTX-and the eccentric exercise-induced injury models, although the magnitude of change of some mediators (indicated by the fold change scale) was greater in the CTX model (Fig. 3a,b) . We observed an increase in arachidonic acid-derived LTB 4 , prostaglandins (PGE 2 , PGD 2 ) and lipoxins (LXB 4 and 15R-LXA 4 ) in both models at day 1 post-injury (Fig. 3a,b) . Similarly, SPMs derived from EPA and DHA, including RvD2, RvD5 and RvE3, were elevated above baseline in both models at day 1 (Fig. 3a,b) . Amounts of selected lipid mediators showed a similar inverse relationship between pro-inflammatory arachidonic acidderived mediators (LTB 4 , PGF 2α ) and SPMs such as LXB 4 , 17R-RvD1, RvD4 and RvE3, which remained elevated at day 8 post-injury (Fig. 3c,  Supplementary Fig. 1 and Supplementary Table 1c) . We also compared the amount of LTB 4 to that of the total amount of SPMs in the tissue at day 1 and day 8 post eccentric exercise-induced injury to determine the dynamics of the switch in lipid mediator class, which occurred at day 8 compared to day 4 in CTX-induced injury (Fig. 3d ). These results demonstrate that lipid mediator class switching occurs during muscle injury regardless of the stimuli, but that the less severe eccentric exercise-induced injury delays the switch compared to CTX-induced injury.
Lipid mediator signatures are distinct in immune cell subsets. Leukocytes are sources and targets of lipid mediators, although the individual lipid mediator profile of distinct immune cell subsets during injury has not been extensively investigated. Immunohistochemistry analysis of injured muscle at days 0, 1, 2, 4 and 8 post-CTX indicated the complete destruction of the muscle architecture, as indicated by the loss of desmin + myocytes by day 1, and the dynamic accumulation of F4/80
+ macrophages starting at days 1 and 2, and increasing by day 4 (Fig. 4a) . At day 8, the normal skeletal muscle architecture was restored and the F4/80 + macrophages largely disappeared (Fig. 4a) . As indicated by flow cytometry, and in line with previous observations 27 
, Ly6G
+ neutrophils reached maximum accumulation at day 1 post-injury and were rapidly cleared from the tissue by day 4 ( Fig. 4b and Supplementary Fig. 2a,b) , characteristic . Data indicated mean ± s.e.m. and *P < 0.05, ***P < 0.001, ****P < 0.0001 by Sidak's multiple comparison test in two-way analysis of variance (ANOVA). Mean (± s.e.m.) fiber CSA is shown on the right panel. ****P < 0.0001 by two-tailed unpaired Student's t-test and n is equal to at least five biologically independent muscle samples for both panels. c, Relative distribution of lipid classes at selected time points after CTX, expressed as percentages. Color coding, names and abbreviations are shown as inset. d, Quantification of each lipid class at indicated time points after CTX injury. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Dunnett's multiple comparison test in two-way ANOVA. Data are shown as mean ± s.e.m. and n = 3 biologically independent muscle samples for each time point. e, Cumulative lipid composition of four distinct groups of phosphatidyl choline (PC) species at indicated time points post-CTX injury. Phosphatidyl choline species groups contain arachidonic acid, DHA, EPA or other PUFA chains at the sn-2 position of phosphatidyl choline. f, Levels of arachidonic acid, EPA and DHA at indicated time points after CTX injury. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Dunnett's multiple comparison test in one-way ANOVA. Data are shown as mean ± s.e.m. and n = 3 biologically independent muscle samples for each time point.
of the resolution phase. F4/80 + Ly6C hi macrophages accumulated in the tissue starting at day 1 and their numbers peaked at day 2 post-injury, while F4/80
+

Ly6C
lo macrophages appeared on day 2 and their numbers were higher than that of Ly6C hi macrophages on days 4-6 ( Fig. 4b and Supplementary Fig. 2b ). Similar kinetics of leukocyte accumulation were observed in the eccentric exercise-induced injury model, where Ly6G + neutrophils and Ly6C hi macrophages peaked at day 1 post-injury, and Ly6C lo macrophages were higher than Ly6C hi macrophages at day 4 post-injury ( Supplementary  Fig. 2c-f ). Using fluorescence-activated cell sorting (FACS), we isolated Ly6G + neutrophils and both Ly6C hi and Ly6C lo macrophages from muscle at days 1-4 post-CTX to assess their lipid mediator profiles by LC-MS/MS (gating strategy in Supplementary Fig. 2a,b) . Using partial least squares-discriminant analysis (PLS-DA) to compare global lipid mediator profiles between each sorted leukocyte population, we observed a partial overlap between the lipid mediator profile of Ly6G + neutrophils (day 1) and that of Ly6C hi and Ly6C lo macrophages (day 2) (Fig. 4c) . In contrast, the lipid mediator profile of Ly6C hi and Ly6C lo macrophages at day 4 were distinct from each other and were clearly separated from Ly6G + neutrophils (day 1) and Ly6C hi and Ly6C lo macrophages (day 2). To determine the changes in individual lipid mediators driving the separation or overlap among Ly6G + neutrophils, Ly6C hi macrophages and Ly6C lo macrophages at each day, the lipid mediator profiles were subjected to hierarchical clustering. Ly6G
+ neutrophils (day 1) contained higher amounts of arachidonic acid-derived pro-inflammatory mediators (for example, LTB 4 and Supplementary Table 1d ). While Ly6G + neutrophils contained SPMs, macrophages produced higher amounts, with a distinct SPM cluster (for example, MaR1, 15R-LXA 4 , RvE3, RvE2, MaR2, RvD5, RvD6) observed at day 4 in both Ly6C hi macrophages and Ly6C lo macrophages (Fig. 4d) . The Ly6C hi macrophages (day 2) had increased production of pro-inflammatory mediators (for example, LTB 4 , PGE 2 ), similar to Ly6G + neutrophils, relative to Ly6C lo macrophages (Fig. 4d) . The amount of RvD2, LXB 4 , LXA 4 and RvD5 was higher in Ly6C lo macrophages compared to Ly6C hi macrophages at day 2 ( Fig. 4d) .
We next calculated the LTB 4 to SPM ratio in each population, as an index of inflammation-resolution. The ratio was highest in Ly6G hi and Ly6C lo macrophages) populations at the indicated day post-CTX. Each column represents the mean of at least three samples for each cell population per time point. e, The ratio of LTB 4 to total SPMs, as described previously, in each cell population at the indicated day post-CTX. Data show mean ± s.e.m. and n is equal to at least three per population per time point. f, Venn diagram presenting the number of identified lipid mediators from whole muscle tissue and from the sorted immune cell populations. g, Normalized mRNA levels; visualized as log 10 (norm.expr.), of selected genes involved in lipid metabolism and signaling from Ly6C hi and Ly6C lo macrophages of days 2 and 4 post-CTX and PMNs RNA-seq analysis (Ward's clustering algorithm and Euclidean distance measure; n = 3 independent samples for each cell population at the indicated time points). neutrophils and Ly6C hi macrophages at day 2 and was reduced in both Ly6C hi macrophages and Ly6C lo macrophages at day 4 ( Fig. 4e) . When we integrated the data from the whole muscle with the data from sorted cells, most lipid mediators (34 in total) were commonly identified between the two datasets (Fig. 4f) . Given the dynamic signatures of lipid mediators between the leukocyte subsets, we next investigated the gene expression of enzymes and cellular receptors that regulate the production and downstream actions of lipid mediators. We performed RNA-seq analysis of Ly6G + neutrophils, Ly6C hi macrophages and Ly6C lo macrophages sorted from muscle at days 1, 2 and 4 following CTX injury. Several members of the phospholipases responsible for the release of PUFA from membrane lipids (for example, Pla2g4a, Pla2g7, Pla2g15) were identified in Ly6G
+ neutrophils, Ly6C hi macrophages and Ly6C lo macrophages ( Supplementary Fig. 3 ). Expression of Pla2g4a, coding for cPLA 2 , was modestly higher in Ly6C hi macrophages and Ly6C lo macrophages than Ly6G
+ neutrophils ( Supplementary Fig. 3 ). Ptgs1 and Ptgs2 (encoding cyclooxygenase 1 and 2) and Ptges (prostaglandin E-synthase) were highly upregulated in Ly6G + neutrophils at day 1 compared to the Ly6C hi and Ly6C lo macrophages at days 2 and 4 ( Fig. 4g) , consistent with the relatively higher amounts of prostanoids (for example, PGE 2 ) in sorted Ly6G
+ neutrophils (Fig. 4d) . Hpgds (encoding hematopoietic prostaglandin-D synthase) was relatively higher in Ly6C lo macrophages compared to Ly6G + neutrophils at day 1 ( Fig. 4g) , consistent with the identification of PGD 2 in days 2 and day 4 Ly6C lo macrophages. Similarly, the leukotriene biosynthetic enzymes Alox5 and Alox5ap, as well as the leukotriene receptor Ltb4r1 were expressed highly in Ly6G
+ neutrophils, while expression of Alox5ap and Lta4h remained constant in Ly6C hi and Ly6C lo macrophages at days 2 and 4 ( Fig. 4g) . The SPMs identified required co-operation of both Alox5 and Alox15 for their biosynthesis 11 ; expression of Alox15 was higher in days 2 and 4 Ly6C hi and Ly6C lo macrophages compared to Ly6G + neutrophils (Fig. 4g) . Fpr2 (encoding FPR2), the receptor for LXA 4 and RvD1, was expressed in Ly6C hi and Ly6C lo macrophages at days 2 and 4, but was higher in Ly6G + neutrophils (Fig. 4g) , consistent with the role of SPMs as stop signals for neutrophil trafficking 11 . In contrast, Gpr18, the receptor for RvD2 28 , peaked in day 4 Ly6C hi macrophages, was expressed in day 4 Ly6C lo macrophages and had low expression in Ly6G + neutrophils (day 1) (Fig. 4g) .
To determine whether interference with the dynamic production sequence of the bioactive lipids affected immune cell trafficking and macrophage subtype specification, mice undergoing CTX injury were treated with the non-steroidal anti-inflammatory drug ibuprofen (IBP) every 24 h and lipid mediator production and leukocyte dynamics were assessed at days 1, 2 and 4 post-injury. Acute treatment (24 h) with IBP strongly inhibited the appearance of COX products (for example, PGE 2 , TXB 2 ) when assessed 4 h after its administration ( Supplementary Fig. 4a,b and Supplementary  Table 1e ). Daily administration of IBP resulted in dysregulated lipid mediator profiles at days 2 and 4, with the amounts of the main lipid mediator pathways being increased when assessed 24 h post-IBP administration compared to mice without IBP treatment ( Supplementary Fig. 4c and Supplementary Table 1f ). The number of CD45
+ cells was not different between mice treated without or with IBP at either day 2 or day 4 ( Supplementary Fig. 4d ). IBP treatment increased the percentage of Ly6C hi macrophages and decreased the percentage of Ly6C lo macrophages at day 2, while the opposite pattern was observed at day 4 ( Supplementary Fig. 4e,f) . These data indicate that interfering with lipid mediator production alters the kinetics of Ly6C hi and Ly6C lo macrophage accumulation.
RvD2 induces specific macrophage gene-expression changes. We next investigated the potential mediators of macrophage-dependent tissue repair. We focused on RvD2 because it is a potent regulator of resolution of inflammation 11, 14 ; it was produced in a dynamic fashion primarily by Ly6C lo macrophages; the gene encoding its receptor, Gpr18, was expressed in Ly6C hi macrophages and it was detected in both CTX-and eccentric exercise-induced muscle injury. RvD2 potently enhances macrophage functions, such as efferocytosis 14, 28 . However, how RvD2 affects gene expression in naïve macrophages remains incompletely characterized. We performed RNA-seq on bone marrow-derived macrophages (BMDMs) treated with RvD2 for 4 h and compared to untreated (control-vehicle) BMDMs. A total of 751 genes were differentially expressed (fold change >1.5; P < 0.05; Supplementary Table 2a) . Among the top 120 differentially expressed genes, on the basis of the largest foldchange differences (absolute value), genes most highly induced by RvD2 included those involved in arginine metabolism (Arg2), transcriptional regulators (Nr4a1, Nr4a2), G-protein and cAMP signaling (Gpr35, Akap3, Adcy1, Arrdc3, Pde4b) and host defense (Rsad2, Tlr5, Gbp5, Gbp10, Masp2) (Fig. 5a ). Functional classification of the differentially expressed genes with gene ontology analysis revealed multiple categories belonging to macrophage activation, function and immune system regulation ( Fig. 5b and Table 3a ). Gene ontology analysis of the differentially expressed genes (fold change >2, P < 0.05) from the two comparisons indicated these genes were involved in processes such as extracellular matrix organization, cell killing, locomotion, migration and muscle tissue development ( Supplementary Fig. 5a and Supplementary  Table 3b ). Genes differentially expressed in Ly6C lo macrophages from day 2-4, included genes involved in actin filament and sarcomere organization, muscle cell differentiation and development, as well as cell proliferation and cell-cell adhesion ( Supplementary  Fig. 5b and Supplementary Table 3c ). We next compared the genes modulated by RvD2 treatment in BMDMs, with the genes identified during the inflammatory (day 2) and repair (day 4) phase using GeneVenn software 30 . This analysis indicated that 172 genes were common between the differentially expressed genes of the three groups comparison: day 2 Ly6C hi versus day 4 Ly6C hi , day 2 Ly6C lo versus day 4 Ly6C lo and control-vehicle versus RvD2 treatment in BMDMs (Fig. 5c,d and Supplementary Table 3d ). Several of these genes, such as Rsad2, Cd83, Rgs2, Abcd2, Il16, Arap3, Usp18, Cxcl10, Pydc4, Gbp3 and Mx1, were among the most highly expressed genes in the RvD2 treatment group, and their expression was higher in day 4 Ly6C lo macrophages than in day 2 Ly6C hi macrophages (Fig. 5d ). Similar gene cluster relationships were observed in those with more moderate overall expression, but which were highly induced selectively in both day 4 Ly6C hi and day 4 Ly6C lo macrophages, such as Elmo3, Gdf9, Slc13a3, Hist3h2a, Kbtbd11, Gbp6, Gbp5 and Pydc3 (Fig. 5d) . Gene ontology analysis of the common-identified differentially expressed genes revealed that they were involved in functions related to mitotic cell cycle and cell division, and processes that included defense responses and response to cytokine stimulus and virus ( Supplementary Fig. 5c and Supplementary Table 3e ). We validated selected individual genes (that is, Cxcl10, Gpr30, Nr4a1, Gpr35) by quantitative PCR with reverse transcription (qRT-PCR) and found that RvD2 induced their expression in a time and concentration-dependent manner (Supplementary Fig. 5d ). These results indicate that RvD2 induced a unique macrophage phenotype, which had some similarities to that detected in the in vivo isolated day 4 Ly6C hi and Ly6C lo macrophages, during the initial phase of repair.
RvD2 is an effector of macrophage subtype specification. We next asked whether exogenous delivery of RvD2 in mice undergoing CTX injury can modulate the accumulation of Ly6C lo repair macrophages, a process that is widely documented to facilitate repair 31 . Since muscle regeneration in healthy mice is tightly coordinated and evolutionary conserved, with a very small window for intervention, we used a model of impaired muscle regeneration to test the effects of RvD2 in aiding the recovery from the injury. For this, we used a CTX injury model in which BoyJ congenic mice are irradiated to deplete satellite muscle cells, followed by BMT from healthy C57Bl/6J donor mice (described in Methods) 32 . In this model, the in situ transition from Ly6C hi to Ly6C lo macrophages is delayed due to the altered cellular composition caused by the radiation and is associated with severe impairment in tissue regeneration 32 . Mice were left to recover for hi versus Ly6C lo at days 2 or 4). Hierarchical clustering analysis was conducted for the transcript levels of the differentially expressed genes (Ward's clustering algorithm and Euclidean distance measure; n = 3 biologically independent samples for each cell populations at indicated time points). 8 weeks following BMT to exclude short-term radiotoxicity effects. At this time point, circulating and muscle-infiltrating myeloid cells are almost exclusively of CD45.2 + donor origin 32 . The chimeric mice were injured with CTX, followed by local intramuscular administration of RvD2 or saline as control either at day 2 or 3 post-CTX. The dose used (4 µg kg ) achieved acute intramuscular amounts of RvD2 (~200 pg at 2 h post-injection), which were commensurate with the endogenous amount of RvD2 quantified during CTX injury at day 2 ( Fig. 2e) , as assessed using intramuscular injection of deuteriumlabeled d 5 -RvD2 into healthy mice to differentiate injected RvD2 from endogenous RvD2 ( Supplementary Fig. 6a,b) . Four days after muscle injury, CD45
+ immune cells (Fig. 6a) (Fig. 6b) were detected in skeletal muscle of the RvD2-treated chimeric mice. In the saline-treated chimeric mice, Ly6C lo macrophages constituted only a small fraction (~10%) of the CD45 + cells, while in day 2 RvD2-treated mice, the frequency of Ly6C lo macrophages increased to 16% (Fig. 6b,c and Supplementary  Fig. 6c ), shifting closer to that observed in healthy mice undergoing regeneration at this time point (~45%; Supplementary Fig. 2b ). Compared to saline treatment, administration of RvD2 at day 3 postinjury compared to administration at day 2 post-injury, resulted in an even higher increase in the frequency of Ly6C lo macrophages (~20%), while the frequency of Ly6C hi macrophages was reduced by 10% compared to vehicle treated animals ( Fig. 6c and Supplementary   Fig. 6c ). More specifically, the ratio of Ly6C lo /Ly6C hi macrophages at day 4 increased from 0.22 in the saline-treated mice, to 0.36 and 0.41 on RvD2 treatment at days 2 and 3 post-CTX injury, respectively ( Supplementary Fig. 6c ). These results indicated that RvD2 regulated the population transition from inflammatory Ly6C hi macrophages to repair Ly6C lo macrophages. To further test whether RvD2 treatment affected inflammation and repair of injured muscle, we assessed the uptake of fluorescently labeled 2-deoxy-d-glucose (2-DG), using in vivo imaging 32 . The 2-DG is taken up by cells with high metabolic activity, such as invading macrophages, and thus is widely used as a non-invasive method to monitor inflammation 29, 32, 33 . Chimeric mice were injured with CTX, treated with RvD2 or saline control intramuscularly at day 3 and injected with 10 nmol 2-DG intravenously 3 h before the imaging on day 4 post-CTX (see Methods). The 2-DG uptake and labeling intensity at day 4 post-CTX injury, expressed as average radiant efficiency, decreased 40% following RvD2 administration at day 3, compared to saline-treated controls ( Fig. 6d and Supplementary  Fig. 6d ), supporting a pro-resolution role of RvD2. To test the functional consequence of RvD2 administration on muscle recovery, we assessed tibialis anterior muscle mass at day 8, and tibialis anterior twitch and tetanus force at days 8 and 14 after CTX-induced injury in vivo. RvD2 improved muscle force recovery by roughly 50% at both time points, compared to saline-treated chimeric mice and increased muscle mass by 17% (Fig. 6e,f and Supplementary  Fig. 6e ), suggesting accelerated muscle regeneration following RvD2 treatment. Collectively, these results suggest that RvD2 can improve muscle recovery following injury, potentially by increasing the ratio of Ly6C lo /Ly6C hi macrophages.
Discussion
Here we described the dynamic regulation of the mediator lipidome during skeletal muscle inflammation and regeneration. Sorted neutrophils and Ly6C hi and Ly6C lo macrophages recapitulated the temporal profiles obtained from whole muscle and revealed a distinct pro-resolving signature expressed by Ly6C lo macrophages. Integration of transcriptomics and lipidomics results demonstrated that Ly6C + macrophages are both sources and sensors of lipid mediators that probably facilitate macrophage population phenotypic transitions.
We observed a marked remodeling of structural lipids in the injured muscle. The liberation of PUFA from phospholipids is classically defined as the rate limiting step in lipid mediator biosynthesis and occurs by calcium-dependent PLA 2 in response to agonists (for example, pattern recognition receptors, purinergic receptors), although secreted PLA 2 , can also play a role 12 . Direct delivery of PUFA to inflammatory exudates can also facilitate lipid mediator production 34 . The increase in lipid mediators mirrored the appearance of PUFA, with distinct temporal regulation observed among pro-inflammatory and pro-resolving mediators, coincident with the differential expression downstream biosynthetic enzymes. These results are similar to those reported in other models of acute sterile and infectious inflammation, such as peritonitis 15, 35, 36 . As an index of this response, the ratio of LTB 4 to the total amount of SPMs decreased from day 2 to day 4 post-injury. This ratio has been associated with chronic inflammation in diseases such as atherosclerosis in humans 37, 38 . We used two models of injury to validate the robustness of the data. CTX causes severe muscle damage and synchronous regeneration 9 , while the eccentric exercise-induced injury results in a less severe muscle damage and is more pathophysiologically relevant 25, 26 . We identified a similar profile of lipid mediators in both models, but with a higher magnitude of change in lipid mediator amounts in the CTX model. Resistance exercise in humans also increases levels of leukotrienes, prostanoids and SPMs, the production of which is negatively affected by ibuprofen 39 . We observed that ibuprofen inhibited prostanoids acutely, but that prostanoids and other lipid mediators rebound after each dose, further demonstrating that lipid mediator pathways are highly connected 36 . The integration of the muscle lipid mediator profiles induced by CTX injury with sorted neutrophils and macrophages showed high overlap, indicating that leukocytes were probable sources of these lipid mediators in the tissue. The contribution of macrophages to SPM production is consistent with a study demonstrating that macrophage depletion decreases SPM levels in vivo 40 . Levels of several SPMs were higher in Ly6C lo macrophages at day 2, while an SPM cluster was observed in both macrophage subsets at day 4, coincident with expression of Alox15. These results are consistent with a report showing that Alox15 is highly expressed in resolution-phase macrophages 41 . Similarly, IL-4 stimulation of human macrophages increases SPMs relative to macrophages polarized with IFN-γ or LPS in vitro 42 . SPM biosynthesis can also be regulated through heterotypic leukocyte interactions (for example, PMN-macrophage) or leukocyte-epithelial or endothelial interactions 11 . Given the relatively high amounts of SPMs precursors in macrophages isolated at day 4 post-injury (for example, 17-HDHA, 15-HETE, 18-HEPE), it is possible that these intermediates were transferred to other cells for conversion to SPMs.
We observed the production of RvD2 by Ly6C lo macrophages at day 2 post-injury and expression of its receptor, Gpr18, in Ly6C hi macrophages. Treatment with RvD2 caused a shift in the frequency of Ly6C hi macrophages and Ly6C lo macrophages in vivo and also lead to improvement in muscle function. Future studies using focused approaches are required to assess if macrophage phenotype is modulated by RvD2 in vivo. Transcriptomics indicated that RvD2 induced the expression of genes in BMDMs that overlapped with genes expressed in both Ly6C hi and Ly6C lo macrophages. These included genes important in host defense, chemotaxis and proliferation, the last of which are characteristic of resolving macrophages 41 . Some of the genes induced by RvD2 in BMDMs would be expected to enhance host defense to both viral and bacterial pathogens, and RvD2 has been reported to enhance host defense and improve survival in sepsis 14, 43 . RvD2 also promotes muscle regeneration and revascularization after ischemia; genes induced by RvD2 in BMDM, such as Vegfa, could underlie these effect 44 . In macrophages, the RvD2-GPR18 axis is also important for enhancing phagocytosis and activating STAT3 43 , which is important for efferocytosis and M2 polarization 45 . In contrast, RvD2 reduces necrosis and stimulates reepithelialization of wounds in part through direct actions on keratinocytes, indicating that RvD2 might engage multiple cellular targets during tissue repair 21, 46 . Along these lines, PGE 2 targets muscle-specific stem cells to promote regeneration 47 while RvE1 regulates signaling in skeletal muscle myotubes 48 . Several SPMs target fibroblasts, endothelial cells and epithelial cells as well 11 . Thus, the resources generated here could inform new roles of lipid mediators and their receptors in muscle inflammation, fibrosis, angiogenesis and regeneration. Integration of transcriptomic, lipidomic, epigenomic and (phospho)-proteomic landscapes could lead to new directions in the understanding of immune cell function and could identify pathways amenable to the development of novel therapeutics.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41590-019-0356-7. Acute CTX muscle injury. Mice were anesthetized with isoflurane (adjusted flow rate or concentration to 1.5%) and 50 µl of CTX (12 × 10 −6 M in PBS) (Latoxan) was injected in the tibialis anterior muscle 49 . Muscles were recovered for flow cytometry analysis, histology, immunohistochemical analysis and lipidomics at days 0, 1, 2, 4 and 8 post-injury. For ibuprofen treatments, mice were treated intraperitoneally with either 100 mg kg −1 ibuprofen (Cayman Chemical; item no. 15687-27-1) or vehicle (DMSO) at day 1, 2 and 3 post-CTX injury (see scheme in Supplementary Fig. 4 ).
Histological analysis of muscle regeneration. Muscles were removed and snap frozen in nitrogen-chilled isopentane (-160 °C), then 8-µm-thick cryosections were cut and stained with H&E. For each histological analysis, at least five slides (per condition) were selected where the total regenerative region inside the CTXinjured tibialis anterior muscle was at least 70%. For each tibialis anterior muscle, myofibers in the entire injured area were counted and measured. H&E muscle sections were scanned with Mirax digital slide scanner and the CSA was measured with HALO software (Indica Labs). CSAs for these samples are reported in µm 2 .
Eccentric exercise-induced muscle injury model. Animals were maintained in a surgical plane of anesthesia (3-5% isoflurane delivered in 100% O 2 ) for the duration of procedure. Anesthetized mice were placed on a warm heating pad and hair was removed from hind limbs using fine electric hair clippers. The hind limb was restrained at the knee firmly with a clamp to ensure that the animal's knee did not move, and the foot strapped to a footplate/force transducer with a dual motor-arm attached (Aurora Scientific). Two 30 g needle platinum electrodes were inserted intramuscularly into the thigh of the right leg, then the sciatic nerve was stimulated by an electric pulse of 100 Hz at 200 μs pulse width at 2.5 mA and 25 V for 0.4 s. While the muscle is under contraction, the motorized footplate applies an eccentric rotational torque, causing micro-trauma and a resultant force deficit to muscle fibers. This protocol was repeated 40 times to create a significant and physiologically relevant injury to the muscle. The experimental mice were then allowed to recover for a period of anywhere from 1-14 days, and followed for muscle contraction force recovery after injury. Mice were killed and muscle tissue was collected for lipidomics and flow cytometry analysis (see below).
Injury model of delayed muscle regeneration. Recipient congenic BoyJ mice (7 weeks old) were irradiated (total body irradiation) with 11 Gy using an X-rad 320 (Precision X-ray Irradiation Systems) X-ray unit for the ablation of the recipient bone marrow as described previously 32 . Following the irradiation, isolated bone marrow cells (in sterile RPMI-1640 medium) flushed out the femur; tibia and humerus from donor C57Bl/6J mice were transplanted into the recipient mice by retro-orbital injection (20 × 10 6 bone marrow cells per mice). This experimental BMT CD45 congenic model allows the discrimination of donor, competitor and host contribution in hematopoiesis and repopulation efficiency of donor cells (congenic mice with CD45.1 versus CD45.2 that are of donor origin). The efficiency of CD45.2 repopulation was then detected by flow cytometry, 8 weeks following the BMT. In short, a cut at the tail tip of the mice provided a drop of blood that was placed into 0.5 ml PBS + 1% fetal bovine serum (FBS) + 10 U ml
Heparin buffer (samples kept on ice). The cells were directly stained by mouse anti-mouse CD45.2-FITC (clone 104, dilution 1:50) and rat anti-mouse GR1-PE (clone RB6-8C5, dilution 1:50) antibodies (BD Pharmingen) and incubated on ice for 30 min. After two washes with ice-cold PBS/FBS/heparin buffer, cells were resuspended in 0.5-1 ml FACS lysing solution (BD catalog no. 349202). Cells were incubated for 5 min at room temperature then centrifuged the cells (400g, 5 min, 4 °C). We ran the double stained samples on FACS (BD FACS Aria III or MoFlo Astrios) and determined the ratio of donor cells. Blood chimerism was usually around 99% gated on the granulocyte fraction 32 . In parallel, chimeric mice from the same transplantation cohorts were used to validate the donor origin, and chimerism of infiltrating myeloid cells in the injured muscle at day 1 post-CTX (similar ratio of donor cells, as we described previously 32 ). Two months following BMT, the animals were injured with CTX, as described above. For in vivo RvD2 treatments, mice where treated intramuscularly with either 4 µg kg −1 RvD2 (Cayman Chemical, item no. 10007279) or saline at day 2 or 3 post-CTX injury.
In vivo muscle force measurement. To determine the effect of RvD2 on muscle function, we performed force measurements in the murine model of delayed regeneration, as described above. In these experiments, mice were treated with RvD2 at day 3 post-injury. For this, mice were first anesthetized with 3% vaporized isoflurane mixed with O 2 . Mice were then positioned under a heat lamp to maintain the body temperature at 37 °C. Knees of the animals were secured to a fixed steel post, and their feet were taped to the platform to prevent movement from the contraction of other muscle groups. Electrical stimulations were applied across two needle electrodes placed through the skin just above the knee and beneath the tibialis anterior muscle to stimulate the tibial nerve. In all measurements, we used 0.1-ms pulses at a predetermined supramaximal stimulation voltage. Tibialis anterior muscles were stimulated with a single 0.1-ms pulse for twitch force measurements and a train of 150 Hz for 0.3-s pulses for tetanic force measurements. A 2-min rest was given to the animal while under anesthesia to allow muscles to return to normal function after tetanus. We performed five twitch and then five tetanic measurements on each muscle, with 2-3 min of recovery between each measurement. For recording the muscle force measurements, we used the 610A Dynamic Muscle Control software from Aurora Scientific.
In vivo small animal FLI imaging using 2-DG. To determine whether RvD2 modulates inflammation in vivo, we performed imaging of 2-DG uptake in the delayed model of regeneration (see above). For this, mice were treated with RvD2 at day 3 post-CTX injury. During the light cycle to minimize muscle activity, BoyJ chimeric mice were intravenously injected with 10 nmol of XenoLight RediJect 2-DG 750 probe (Perkin Elmer) or control 750 dye (in 0.2 ml volume) and imaged at 3 h with IVIS Spectrum (Ex745 nm/Em820 nm). Specifically, 3 h after 2-DG injection animals were anesthetized by 3% isoflurane with a dedicated small animal anesthesia device and whole body FLI scans were acquired using the IVIS Spectrum system (Caliper LifeSciences). To prevent movement, the animals were fixed to the mouse chamber and positioned in the center of field of view. We acquired FLI using a 3-s exposure with field of view of 6.5. Digital images were recorded and analyzed using Living Image v.4.7.2 software (IVIS Imaging Systems). We analyzed images with a consistent region of interest placed over each hind limb to calculate a fluorescence signal. We calculated the fluorescence signal in average radiance efficiency ((p s
Immunohistochemistry. Tissue sections were fixed and permeabilized in icecold acetone for 5 min and blocked for 30 min at 20 °C (room temperature) in PBS containing 2% bovine serum albumin (BSA). Tissues were stained for 1 h at room temperature using a primary antibody diluted in 2% BSA. Isolation of macrophages from CTX-injured skeletal muscle. Tibialis anterior muscles from CTX-injured animals were carefully isolated with fine scissors and fascia was removed 49 . Despite alterations in the integrity of the muscle tissue during injury (for example, swelling), the tissue remains intact during collection. Muscles were weighed and then placed directly into ice-cold PBS. Muscles were then dissociated in RPMI containing 0.2% collagenase B (Roche Diagnostics) at 37 °C for 1 h and filtered through a 100 µm and a 40 µm filter. CD45 + cells were isolated using magnetic sorting (Miltenyi Biotec). For FACS, macrophages were incubated with Fcγ receptor blocking antibodies and with 10% normal rat serum: normal mouse serum 1:1 mix, then stained with a combination of PE-conjugated anti-Ly6C antibody (HK1.4, eBioscience), APC-conjugated F4/80 antibody (BM8, eBioscience) and FITC-conjugated Ly6G antibody (1A8, Biolegend F4/80 neg neutrophils were quantified. In each experiment, samples were processed in parallel to minimize experimental variation. Cells were analyzed on a BD FACSAria III or MoFlo Astrios sorter (Summit v.6 software) and data analysis was carried out using BD FACSDIVA and FlowJo V10 software. The gating strategy is shown in Supplementary Fig. 2a,b. Shotgun lipidomics. Muscle samples were collected from mice and pulverized into a fine powder using a stainless steel biopulverizer at the temperature of liquid nitrogen. The tissue powders of 10-20 mg were weighed and homogenized in 0.5 ml 10× diluted PBS in 2.0 ml cryogenic vials (Corning Life Sciences) by using a digital sonifier (Branson 450). Protein assay on the homogenates was performed using a bicinchoninic acid protein assay kit (Thermo Scientific) with BSA as standards. The rest of homogenate was accurately transferred into a disposable glass culture test tube, and a mixture of lipid internal standards was added before lipid extraction for quantification of all reported lipid species. Lipid extraction was performed by using a modified Bligh and Dyer procedure as described previously 50 . Individual lipid extracts were resuspended into a volume of 100 μl of chloroform:methanol (1:1, v/v) per mg of protein and flushed with nitrogen, capped and stored at −20 °C for lipid analysis. For ESI direct infusion analysis, lipid extracts were further diluted to a final concentration of ~500 fmol µl −1 , and analysis was conducted on a QqQ mass spectrometer (Thermo TSQ QUANTIVA) equipped with an automated nanospray device (TriVersa NanoMate, Advion Bioscience Ltd). Identification and quantification of lipid molecular species were performed using an automated software program [50] [51] [52] . Data were normalized per mg of protein.
Lipid mediator identification and quantitation by LC-MS/MS. Samples of muscle tissue (tibialis anterior) or flow-sorted leukocyte populations isolated from injured muscle were subjected to solid phase extraction (SPE) followed by a targeted LC-MS/MS analysis. For muscle samples, tissue was minced with scissors in ice-cold methanol containing deuterated internal standards and stored at −80 °C. For leukocyte samples, cells were isolated from CTX-treated muscle then flow sorted and plated in phenol red-free and serum-free medium. The cells and medium were then combined with two volumes of ice-cold methanol and deuterated internal standards were added. Samples were then stored at −80 °C. Deuterated internal standards (d 5 4 ; Cayman Chemical) were used to assess extraction recovery and quantification. Samples were centrifuged (3,000 r.p.m.) and supernatants were then subjected to SPE and LC-MS/MS analysis, as described previously 53 . In short, acidified water (pH 3.5 with HCl) was added to samples immediately before SPE using C18 column chromatography. Lipid mediators were eluted in the methyl formate fractions, the solvent was evaporated under a gentle stream of N 2 gas and the samples were then resuspended in a methanol water solution (50:50) . Samples were then injected using a high-performance liquid chromatograph (Shimadzu) coupled to a QTrap5500 mass spectrometer (AB Sciex) operating in negative ionization mode. Individual lipid mediators were identified using specific MRM transitions, information-dependent acquisition and enhanced product ion scanning 54 . Identification was based on matching retention time with authentic standards, MRM transitions and diagnostic tandem mass-spectrometry fragmentation ions. Quantitation of mediators was then carried out on the basis of the extraction recovery of the deuterated internal standards and calibration curves of external standards for each individual mediator.
Statistical analysis of PUFA-derived lipid mediators. Once each individual lipid mediator was quantitated, profiles for each sample set were constructed. These profiles were then subjected to further analyses using two statistical software platforms. Using the Metaboanalyst tool 55 (www.metaboanalyst.ca), the data first underwent a missing value imputation in which half the minimum positive value was inserted for compounds that were not detected in all samples. A generalized log transformation was then performed and the data were autoscaled. Once these preliminary functions were completed, hierarchical cluster analysis using an Euclidean distance measure and Ward's clustering algorithm was performed to create heatmaps. PLS-DA was also conducted for the isolated leukocyte samples. In some cases, lipid mediator profiles were also subjected to interaction network pathway analysis using Cytoscape 56 (Cytoscape.org).
Quantification of deuterium-labeled RvD2 in tibialis anterior muscle.
Mice were anesthetized with 2% isoflurane (with 2 l min −1 O 2 ) and placed on a temperature-controlled water blanket to maintain a body temperature of 37 °C. Once anesthetized, 50 µl of 4 µg kg −1 deuterium-labeled (d 5 )-RvD2 (Cayman Chemical) in saline was injected into the tibialis anterior muscle. One, two or three hours later the muscles were removed and immediately placed in ice-cold methanol containing d 8 -5-HETE and d 5 -LXA 4 . The tissue was minced with surgical scissors then subjected to LC-MS/MS targeted lipidomic analysis as described above.
Isolation and in vitro differentiation of macrophages from murine bone marrow. Bone marrow was flushed from the tibiae and femurs of 8-10-weekold male C57BL/6J mice using a 25-gauge needle and DMEM media (ATCC) containing 10% FBS, 20 mM HEPES and 1% penicillin/streptomycin. Once isolated, the bone marrow was plated in this medium supplemented with 10 ng ml −1 M-CSF (macrophage colony-stimulating factor; Sigma). On day 4 of differentiation, the media was replenished with fresh media (containing M-CSF). After 7 days, the cells were liberated using a cell scraper centrifuged and replated in media lacking M-CSF. After 24 h, cells were exposed to 10 nM RvD2 (Cayman Chemical) for 4 h then collected in Buffer RLT (Qiagen) with 10 µl ml
RNA isolation. Total RNA was isolated with TRIZOL reagent according to the manufacturer's recommendation. Then, 20 ug glycogen (Ambion) was added as carrier for RNA ethanol precipitation.
qRT-PCR. BMDMs were treated with 0.1, 1.0 or 10 nM RvD2 for 3 or 4 h. The cells were then dissociated and collected in RLT lysis buffer (Qiagen) and subjected to RNA extraction using the RNeasy Mini Kit with on-column DNase treatment (Qiagen) according to the manufacturer's instructions. Reverse transcription and complementary DNA synthesis were performed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR was carried out using the SsoAdvanced Universal SYBR Green Supermix on a CFX RT-PCR Detection System with a C1000 Thermal Cycler (Bio-Rad) with verified qRT-PCR primers for Cxcl10, Gpr30, Nr4a1, Gpr35 and Hprt (SA Biosciences). Data are presented as relative expression determined by the 2 −ΔΔCT method after internal normalization to expression of Hprt.
RNA sequencing (RNA-seq) library preparation. cDNA library for RNA-seq was generated from 100-400 ng total RNA using TruSeq RNA Sample Preparation Kit (Illumina) according to the manufacturer's protocol. Briefly poly-A tailed RNA molecules were pulled down with poly-T oligo attached magnetic beads. Following purification, mRNA was fragmented with divalent cations at 85C, and then cDNA was generated by random primers and SuperScript II enzyme (Life Technologies). Second strand synthesis was performed followed by end repair, single ' A' base addition and ligation of barcode indexed adapters to the DNA fragments. Adapter specific PCRs were performed to generate sequencing libraries. Libraries were size selected with E-Gel EX 2% agarose gels (Life Technologies) and purified by QIAquick Gel Extraction Kit (Qiagen). Libraries were sequenced on HiSeq 2500 instrument. Three independent experiments were performed to isolate and sequence each population.
RNA-seq analysis. Tophat2 57 was used to align the reads to the mm10 mouse assembly. Further downstream analysis of the aligned reads was performed using the StrandNGS software (v.2.8, Build 230243) from Strand Life Sciences. There, normalization of the raw read counts was performed using the DeSeq method 58 . One-way ANOVA and Tukey's post hoc test was performed for the normalized counts of BMDMs untreated/RvD2-treated for 4 h, and also of the sorted and isolated neutrophils of day 1, Ly6C hi and Ly6C lo macrophages of days 2 and 4, post-CTX. Changes in genes with a fold change >1.5 and P < 0.05, were considered to be statistically significant and the genes differentially expressed. Heatmaps were drawn using the R package pheatmap. The accession codes for the RNA-seq reported in this paper are SRP145076 (SRA) and GSE114291 (GEO).
Gene ontology analysis. Lists of differentially expressed genes (P< 0.05 and FC > 2) were analyzed using the Panther tool (http://www.geneontology.org/) and the gene ontology enrichment analysis to create a gene ontology. Gene ontologies with P values < 0.05 were selected and results were presented according to their −log 10 P value.
Statistical analysis. In scatter dot plots, mean and s.e.m. are shown in addition to individual data points. In the bar graphs, bars show the mean of the indicated number of samples, error bars represent s.e.m. All experiments were performed using at least three independent experiments from distinct samples. No repeated measures were performed. Student's t-tests and ANOVA analyses were performed in GraphPad Prism 6 (GraphPad Software) with 95% confidence intervals, and P < 0.05 was considered significant (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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Data collection
For muscle force recording we used the 610A Dynamic Muscle Control (DMC) software from Aurora Scientific. BD FACS DIVA version 6 (from Becton Dickinson Biosciences) and Summit v6 (Beckman Coulter) was used for flow cytometry data collection.
Data analysis
For the RNA-seq data, reads were aligned to the mm10 mouse assembly using the Tophat2 (Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions , deletions and gene fusions. Genome Biology 14, R36 (2013), using default parameters. The aligned reads in bam format were then processed for downnstream analysis, upon manufacturer's instructions using the StrandNGS software, Version 2.8, Build 230243. © Strand Life Sciences, Bangalore, India . There, normalization of the raw read counts was performed using the DeSeq method (Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). 1-way ANOVA and Tukey's post hoc test was performed for the normalized counts of untreated/ RvD2 treated for 4 hours BMDMs, and also of the sorted and isolated neutrophils of Day 1, Ly6Chigh and Ly6Clow macrophages of days 2 and 4, post CTX. Changes in genes with Fold Change > 1.5 and p-value < 0,05, were considered to be statistically significant and the genes differentially expressed. Heatmaps were drawn using the R package pheatmap based on the package's options without using a custom made algorithm. To integrate genes modulated by RvD2 in BMDMs and the genes modulated during Ly6Chi to Ly6Clo transition we used the GeneVenn software. For gene ontology (GO) analysis we used the Panther Tool from (geneontology.org).
For the shotgun-lipidomics, identification and quantification of lipid molecular species were performed using an automated software program as described in Yang et al. For targeted lipidomics, data acquisition and peak integration was performed using Analyst version 1.6.2. Downstream data analysis was performed using Metaboanalyst 4.0, as described in Methods. Lipid mediator profiles were also subjected to interaction network pathway analysis using Cytoscape (Cytoscape.org).
For histology, Cross sectional area was measured using HALO software v2.3 (Indica labs) and Muscle Fiber quantification module.
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For flow cytometry (FACS) analysis FlowJo (version 10) was used.
For in vivo small animal FLI, digital images were recorded and analyzed using Living Image 4.7.2 software (IVIS Imaging Systems -Caliper LifeSciences).
For Immunohistochemistry Fiji and Illustrator CS5 (Adobe) were used to assemble the figures.
Prism v6 software (Graphpad) was used to generate graphs and perform statistical analysis.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The accesion numbers for the RNA-seq data can be found at the GEO: GSE114291 and SRA: SRP145076 repositories and both have been assigned to the Bioproject: PRJNA: 466152. Figures do not have associated raw data. Normalized expression data of the RNA-seq and concentrations of the lipidomics data can be found in supplementary tables, which are provided.
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Sample size
No statistical methods were used to predetermine the sample size. Sample size was chosen to be equal or greater to 3 in every condition tested as it is the minimum required number to have a standard deviation. In addition, statistical analysis and post-hoc tests were perfomed to verify the significance of the findings.
Data exclusions No data were excluded from the analysis.
Replication
Replicates were equal or greater to 3 for each experimental condition and the replication was successful.
Randomization Samples were randomly allocated into experimental groups.
Blinding
Investigators were not blinded to group allocations. For RNA-seq analyses and for targeted LC-MS/MS, the analysis is objective and based on predetermined identification criteria (i.e., retention time as compared with authentic standards, see Methods).
For cross sectional area analysis blinding of the histological samples was used. For RvD2 treatments group allocation blinding was used during data collection and analysis.
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